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Introduction
The recent evolution of computed tomography (CT)-based implant planning and dosimetry has sparked renewed interest in using high-dose rate (HDR) intracavitary brachytherapy for the treatment of nasopharyngeal carcinoma (NPC) [1, 2] . The CT-based techniques have accurately reconstructed the position of all intracavitary applicators with respect to the patient's anatomy, thereby demonstrating the spatial dose distributions to the tumor volume and neighboring structures. By optimizing the relative dwell times for each activated dwell position, the radiation doses are best conformed to the NPC whilst sparing more of the normal tissues like brain stem, spiral cord, temporary lobes, visual apparatus and pituitary gland [3] .
However, when HDR brachytherapy is used, the treatments must be executed very carefully. A number of factors could potentially lead to substantial dose deviations from the prescription in the chain of HDR treatment [4] . This is mainly due to the fact that the planning and treatment systems tend to be relatively complicated. Significant errors in treatment dose can result from the use of incorrect calculation parameters as well as from machine malfunction [4] [5] [6] [7] . As it has been pointed out recently [5] , these potential errors are quite difficult to be identified and even though all the quality assurance (QA) checks recommended have been implemented, mistakes can happen without detection. This may result in severe radiation injury to patients since HDR brachytherapy delivers very high doses within a short time period. To avoid therapy misadministration as well as to verify the actual doses delivered to the tumor during an HDR treatment, the development of an in vivo dosimetry method as a supplement to existing QA programs is thus very desirable.
Several studies have explored the feasibility of in vivo dosimetry with thermoluminescent dosimeters (TLDs) and semiconductor diodes for HDR brachytherapy [5, [8] [9] [10] . While TLDs are often used in clinical dosimetry due to their small size, they are also known to be tedious to use [11, 12] . The fact that acquiring moderately accurate, reproducible results using TLDs requires stringent calibration, handling and annealing procedures suggests that in vivo thermoluminescence dosimetry would be difficult to implement on a daily basis. Also TLDs are not real time dosimeters so that they are incompetent to provide on-line monitoring of operational mistakes and their immediate corrections. Semiconductor diodes are simpler to use than TLDs. The major disadvantages of diodes are their relatively large size, which makes them unable to be held in a small nasopharyngeal applicator. In addition, some investigations have revealed that diode measurements may need several correction factors for even simple application in clinical radiotherapy [13, 14] .
The MOSFET detector is the most recent development for in vivo dosimetry compared with TLDs and diodes. Incorporating many of the advantages of TLDs and diodes such as small physical size, ease of use and immediate readout, the MOSFET has demonstrated their potential use in HDR brachytherapy [15] [16] [17] . In a previously published study, Zilio and his coworkers proved that the MOSFET detector, with appropriate calibration and correction, could also be used for absolute dosimetry in the context of a microSelectron HDR 192 Ir source, even for situations where photon energy spectra were different from the reference location [15] . More recently, our group has successfully exploited an improved micro-MOSFET design with reduced external dimensions for use in brachytherapy catheters as a means of routine QA to verify brachytherapy dose calculations [16] . These pilot MOSFET dosimetry studies, basically, are limited to the integral dose measurements, in which results are obtained only after a treatment has been delivered. As reported by Gladstone et al [18] and others [19, 20] , the MOSFET detector has an advantage over many other dosimeters in its ability to provide real-time dose information. This will offer extra benefits for treatment monitoring in that it may allow dose errors to be detected at a much earlier stage.
The main purpose of the present study is to provide a real time MOSFET The customization process for the nasopharyngeal applicator is performed under topical anesthesia using nebulized 4% lidocaine hydrochloride applied to the patient's nasal cavity, nasopharynx, and oropharynx. With the guidance of a nasopharyngeal speculum, the applicator is introduced 
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Nasopharyngeal applicator
MOSFET dosimetry system
The applied MOSFET dosimetry system, including the recently developed micro-MOSFET detectors (MOSkin TM ) and a microprocessor based reader, has been previously introduced [16, 21] . One of the major characteristics of this micro-MOSFET detector is its packaging technology, by which the sensor chip is hermetically sealed with a 70-µm thick water-equivalent film. The thin-film encapsulating layer prevents damage to the electronics, and acts as a carrier of the thin aluminum contact leads that are connected to the MOSFET sensor from the top-side.
In this experiment, dose measurements were performed in a real time mode with a positive bias voltage of 5 V applied to the MOSFET during irradiation. This required a connection to a laptop computer and utilization of the "MosPlot" software.
The computer data acquisition system measured periodically the instantaneous voltage signal with the user-defined period (one second in this case). The software MosPlot 4.2 allowed for the online graphical presentation of the change in the threshold voltage V th (i.e. accumulated dose variation) or increments of ⊿V th for consecutive readouts (i.e. differential dose rate).
MOSFET calibration and correction
The calibration process is essentially a two-step process: calibration in a standard set-up to determine the reference calibration factor and subsequently the establishment of a series of correction factors for irradiation conditions deviating from the reference conditions. Iridium source, a reference point at a perpendicular distance of 5 cm from the source was selected [22] . By using a template calibration jig, the dose in water at the reference point was measured with the ionization chamber and the MOSFET detector, respectively. To improve the measurement accuracy, a radiation dose of 50 cGy was delivered to the MOSFET detector every time, which was sufficient to ensure that the response uncertainty associated with the MOSFET reader would equate to less than 1% of the threshold voltage change. The calibration factor, in terms of cGy per mV, was therefore determined for each individual MOSFET.
To overcome the MOSFET sensitivity variation with the energy spectrum in 192 Iridium brachytherapy, an energy dependent correction factor, CF, was introduced for measurement performed at locations other than the calibration position. The CFs, defined as the inverse of MOSFET sensitivities, were measured at five source-to-detector distances ranging from 1 cm to 5 cm with 1 cm increment along the source transverse bisector axis in the water phantom [16] . The derived CF factors were fitted with a least-squares polynomial, whereby the CFs for other positions between 1 cm and 5 cm could be obtained by interpolation. The determined energy dependent correction factors were compared with the published data for a previously used RADFET dosimeter.
The reproducibility of real-time MOSFET dosimetry system
Since the introduction of the automatic data acquisition system in the real time mode may add electronic noise to the signal, the readout reproducibility of the MOSFET dosimetry system in the real time mode was investigated at different dose levels and was compared with dosimeter readings being manually triggered.
Under the calibration set-up, the MOSFET detector was irradiated ten times for each of the following integrated doses: 20, 30, and 50 cGy. The threshold voltage change before and after each irradiation was measured using both the real-time mode and the manual mode. The corresponding coefficients of dispersion of repeated measurements were computed for different applied doses. 
CT-based HDR intracavitary brachytherapy
In vivo dosimetric verification
The HDR treatments were delivered on an outpatient basis once per day for 2 to 4 days. The applicator localization was verified with fluoroscopy each time and orthogonal radiographs were taken for document.
The MOSFET detector was placed into one applicator fixing to its distal blind end, when the other applicator was being used to implement treatment and vice versa. To date, real-time in vivo dosimetry with MOSFET detectors has been performed for a total of 70 measurements of 11 NPC patients. For all the patients, measurements
were followed through the whole treatment sessions.
Results
MOSFET calibration and correction
Five MOSFET detectors were independently calibrated in the water phantom, resulting in a mean dose calibration factor of 0.46±0.012 cGy/mV for the 192 Iridium source.
The energy dependent correction factors between the new micro-MOSFET detector and a previously used RADFET dosimeter provided by the same manufacturer were compared in Figure 2 . The correction factors were plotted against the
Figure 2 Comparison of energy-dependent correction factors between the new
MOSkin TM and a previously used RADFET dosimeter. The RADFET data were derived from the published data [8] , which were re-normalized to the 5-cm value.
source axis distances. The RADFET data were derived from the published data [15] , which were re-normalized to the 5-cm value. The newly developed micro-MOSFET detector showed a relatively flat energy response in the low energy spectrum of the 192 Iridium source compared with the RADFET dosimeter. The maximum sensitivity variation was found to be no more than 7% in the given distance range.
The reproducibility of real-time MOSFET dosimetry system
As the radiation dose increased from 20 cGy to 50 cGy, the reproducibility of the dosimetry system was improved from 3.5% to 1.4% for the manual mode and from 4.8% to 1.9% for the real-time mode (Table 1) . A relatively large deviation in reproducibility tests associated with real-time data acquisition may be partially owing to electronic noise. However, for irradiated dose levels of more than 50 cGy, the real-time mode can also give a reasonable reproducibility of measurements better than 2.0%.
In vivo dosimetric verification
In vivo dosimetric verification was performed for 70 measurements of 11 NPC assessments have deviations within the range of -5% to 7%. The maximum dose discrepancy was 8.3%.
The corresponding dose measurements with MOSFET detectors in each fraction of a particular patient were then averaged and compared with the expected BPS calculated dose. As plotted in Figure 5 , the mean discrepancies between measured and planned doses averaged over all fractions of each patient was -0.2±3.9% (right side) and -0.3±3.7% (left side), respectively. All the patients received a total dose different from the prescription within the tolerance range of -5% to 7%.
7.4.
Discussions
The widespread application of HDR brachytherapy with its inherent dangers necessitates a comprehensive set of QA programs to minimize risks to both patients and medical staff. Besides separate QA checks for each component of the treatment process, in vivo dosimetry which can provide an estimate of the overall error in an HDR treatment has been recommended by many authors [5, 6, [8] [9] [10] .
Due to the small physical size, the MOSFET detector can be conveniently introduced to the nasopharynx via the small nasopharyngeal applicator making it attractive for in vivo treatment verification. Before use each MOSFET detector should be calibrated individually against an ionization chamber in the water phantom. There are some reports that the radiation response of the MOSFETs may not completely linear over the whole voltage range [15, 17] . As a result, a recalibration of the device was performed periodically for every 5-V increment in our experiments.
The MOSFET detectors are known to have photon energy dependence in the low energy range of the
192
Iridium spectrum [15, 23] . The previously published data showed that a correction factor of about 1.27 times greater than the 5-cm value was required in absolute depth dose determination at 1-cm distance from the source for a RADFET dosimeter [15] . In this updated generation products, the energy response of the MOSFET detector in the 192 Iridium spectrum has been optimized by using special encapsulation techniques that avoid high Z materials close to the dosimetric volume.
The sensitivity variation, as shown by our results, was minimized to be within 7% in the clinically relevant distance range of 1-5 cm. This will help improve the dosimetric accuracy of in vivo measurement for HDR brachytherapy.
The reproducibility of MOSFET measurements in the manual mode was found to be 1.4% at the threshold voltage shift of about 100 mV. This result was consistent with previous findings [24] . Due to electronic noise, the real time data acquisition mode exhibited a relatively large deviation in reproducibility tests (i.e. 1.9%).
Considering normal HDR treatments usually deliver a dose that can cause a threshold voltage change higher than 100 mV to the measurement point, it is practically within the measurement uncertainty.
Among kinds of QA problems for HDR brachytherapy, the accurate placement of the applicator is crucial for reliable dose distribution and treatment outcome. Kremer et al developed a computer-assisted device for three-dimensional placement of afterloading probes based on CT scans [25] . With this device, target points have been reached with a mean accuracy of 0.6 mm (maximum deviation was 2.6 mm). At our institution, we treated NPC patients using a customized nasopharyngeal applicator on an individual basis as introduced by Ng et al [3] . By improving the applicator design MOSFET-array dosimeter configuration that can provide a one-dimensional dose profile across the target volume [26] . As the detector array may better serve the purpose of in vivo patient dosimetry, it is now under research by ours and other groups. In future developments the external dimensions of the array dosimeter will be significantly reduced so as to permit its use in brachytherapy applicators. Anyhow, we feel that even with currently designed MOSFETs, the proposed method is capable of detecting errors of major clinical significance.
Conclusion
In vivo measurement using the real-time MOSFET dosimetry system provides a means of overall dosimetry check for the HDR treatment. With detectors placed within the patients' nasopharynx, it is possible to evaluate and document, in real time, the actual dose to the tumor received by the patient during a treatment fraction.
Through an online comparison between the measured dose and the calculated value, the dosimetry system offers another line of security to detect and prevent large errors.
The method we presented here is universal and can be applied in any other cases of clinical interest. derived from the published data [8] , which were re-normalized to the 5-cm value. 
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